Profil
Dr. Mark Forman was previously employed as a Chief Medical Officer by Ventyx Biosciences, Inc., a Chief Medical Officer by Passage Bio, Inc., a Vice President by ACADIA Pharmaceuticals, Inc., and an Executive Director by Translational Medicine Accelerator.
He received his undergraduate degree from Yale University, a doctorate degree from The Rockefeller University and a doctorate degree from Duke University.
Anciens postes connus de Mark Forman
| Sociétés | Poste | Fin |
|---|---|---|
| VENTYX BIOSCIENCES, INC. | Directeur Technique/Scientifique/R&D | 04/03/2026 |
| PASSAGE BIO, INC. | Directeur Technique/Scientifique/R&D | 02/08/2024 |
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | 01/01/2021 |
Translational Medicine Accelerator | Directeur/Membre du Conseil | - |
Formation de Mark Forman
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 7 |
|---|---|
ACADIA Pharmaceuticals, Inc.
ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Rockefeller University
The Rockefeller University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Passage Bio, Inc.
Passage Bio, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of monogenic central nervous system disorders | Health Technology |
Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops oral therapies for patients with autoimmune, inflammatory and neurodegenerative diseases | Health Technology |
Translational Medicine Accelerator |
















